USU Microbiology/Immunology Researchers Awarded Up to $35 Million by NIAID for Scientific Advancements

USU Microbiology/Immunology Researchers Awarded Up to $35 Million by NIAID for Scientific Advancements

Nipah VirusThe Uniformed Services University of the Health Sciences (USU), along with Profectus Biosciences, Inc., the Vanderbilt University Medical Center, Mapp Biopharmaceutical, Inc., and the University of Texas Medical Branch (UTMB), have been awarded up to $24.5 million over 5 years to advance treatments for the highly lethal henipaviruses, Nipah and Hendra. The award, to Dr. Christopher Broder, professor and chair of the Department of Microbiology and Immunology at USU, is a collaborative Center of Excellence for Translational Research (CETR) grant supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).  

In addition, USU, along with Emory University, University of North Carolina, Duke University, University of New Mexico, Oregon State, University of Virginia, and the Food and Drug Administration (FDA), have been awarded up to $10.7  million over 5 years to USU’s Gonorrhea Vaccine Cooperative Research Center to advance promising vaccine candidates towards further preclinical development and clinical trials.  The award, to Dr. Ann Jerse, professor and vice chair of the Department of Microbiology and Immunology at USU, is a U19 cooperative agreement grant supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).